Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care
Alan T. Hirsch,Michael H. Criqui,Diane Treat-Jacobson,Judith G. Regensteiner,Mark A. Creager,Jeffrey W. Olin,Susan H. Krook,Donald B. Hunninghake,Anthony J. Comerota,M. Eileen Walsh,Mary M. McDermott,William R. Hiatt +11 more
TL;DR: The results demonstrate that underdiagnosis of PAD in primary care practice may be a barrier to effective secondary prevention of the high ischemic cardiovascular risk associated with PAD.
read more
Abstract: ContextPeripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis
that is common and is associated with an increased risk of death and ischemic
events, yet may be underdiagnosed in primary care practice.ObjectiveTo assess the feasibility of detecting PAD in primary care clinics,
patient and physician awareness of PAD, and intensity of risk factor treatment
and use of antiplatelet therapies in primary care clinics.Design and SettingThe PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS)
program, a multicenter, cross-sectional study conducted at 27 sites in 25
cities and 350 primary care practices throughout the United States in June-October
1999.PatientsA total of 6979 patients aged 70 years or older or aged 50 through 69
years with history of cigarette smoking or diabetes were evaluated by history
and by measurement of the ankle-brachial index (ABI). PAD was considered present
if the ABI was 0.90 or less, if it was documented in the medical record, or
if there was a history of limb revascularization. Cardiovascular disease (CVD)
was defined as a history of atherosclerotic coronary, cerebral, or abdominal
aortic aneurysmal disease.Main Outcome MeasuresFrequency of detection of PAD; physician and patient awareness of PAD
diagnosis; treatment intensity in PAD patients compared with treatment of
other forms of CVD and with patients without clinical evidence of atherosclerosis.ResultsPAD was detected in 1865 patients (29%); 825 of these (44%) had PAD
only, without evidence of CVD. Overall, 13% had PAD only, 16% had PAD and
CVD, 24% had CVD only, and 47% had neither PAD nor CVD (the reference group).
There were 457 patients (55%) with newly diagnosed PAD only and 366 (35%)
with PAD and CVD who were newly diagnosed during the survey. Eighty-three
percent of patients with prior PAD were aware of their diagnosis, but only
49% of physicians were aware of this diagnosis. Among patients with PAD, classic
claudication was distinctly uncommon (11%). Patients with PAD had similar
atherosclerosis risk factor profiles compared with those who had CVD. Smoking
behavior was more frequently treated in patients with new (53%) and prior
PAD (51%) only than in those with CVD only (35%; P
<.001). Hypertension was treated less frequently in new (84%) and prior
PAD (88%) only vs CVD only (95%; P <.001) and
hyperlipidemia was treated less frequently in new (44%) and prior PAD (56%)
only vs CVD only (73%, P<.001). Antiplatelet medications
were prescribed less often in patients with new (33%) and prior PAD (54%)
only vs CVD only (71%, P<.001). Treatment intensity
for diabetes and use of hormone replacement therapy in women were similar
across all groups.ConclusionsPrevalence of PAD in primary care practices is high, yet physician awareness
of the PAD diagnosis is relatively low. A simple ABI measurement identified
a large number of patients with previously unrecognized PAD. Atherosclerosis
risk factors were very prevalent in PAD patients, but these patients received
less intensive treatment for lipid disorders and hypertension and were prescribed
antiplatelet therapy less frequently than were patients with CVD. These results
demonstrate that underdiagnosis of PAD in primary care practice may be a barrier
to effective secondary prevention of the high ischemic cardiovascular risk
associated with PAD.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Model-based cardiovascular disease diagnosis: a preliminary in-silico study.
TL;DR: The proposed approach may evolve into a viable alternative to the state-of-the-art techniques for cardiovascular disease diagnosis and show superior sensitivity to ankle-brachial index and convenience to carotid-femoral pulse wave velocity.
13
Epidemiology of Chronic Critical Limb Ischemia
Akhil Gulati,Lawrence A. Garcia,Subasit Acharji +2 more
- 01 Jan 2017
TL;DR: Peripheral artery disease is often referred to as a continuum of disease of occlusive arterial syndromes that can range from asymptomatic obstructive disease through Occlusive disease requiring amputation, and chronic critical limb ischemia has a prevalence that is more difficult to define and is quite variable in the published literature.
13
What's new in lower-extremity arterial disease? WOCN's 2008 clinical practice guideline.
Phyllis A. Bonham,Bonny G. Flemister,Margaret Goldberg,Penny Ellen Crawford,Jan J. Johnson,Myra F. Varnado +5 more
TL;DR: An overview of the process used to develop the guideline, a discussion of risks for LEAD, and specific recommendations for assessment, interventions, patient education, and risk-reduction strategies are presented.
13
Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry
Anselm K. Gitt,Claus Juenger,Christina Jannowitz,Barbara Karmann,Juergen Senges,Kurt Bestehorn +5 more
TL;DR: Through infrequent increases in statin doses and mainly through add-on of a cholesterol absorption inhibitor, cardiologists improved target level attainment in high-risk CAD patients.
13
A scoping review of vascular surgery education in the medical school curriculum.
TL;DR: In this article, a scoping review of the available evidence on the provision of vascular surgery education in the medical school curriculum worldwide is presented, and the most important positive determinants when choosing VS as a career were having a VS mentor, the technical aspects of VS, and participation in a VS rotation.
13
References
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
28.6K
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
6.2K
•Journal Article
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).
TL;DR: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.
6K
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
5.5K
Related Papers (5)
Alan T. Hirsch,Ziv J. Haskal,Norman R. Hertzer,Curtis W. Bakal,Mark A. Creager,Jonathan L. Halperin,Loren F. Hiratzka,William R.C. Murphy,Jeffrey W. Olin,Jules B. Puschett,Kenneth Rosenfield,David B. Sacks,James C. Stanley,Lloyd M. Taylor,Christopher J. White,John White,Rodney A. White,Elliott M. Antman,Sidney C. Smith,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Raymond J. Gibbons,Sharon A. Hunt,Alice K. Jacobs,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +29 more
F. G. R. Fowkes,Gordon D Murray,Isabella Butcher,C.L. Heald,R.J. Lee,Lloyd E. Chambless,Aaron R. Folsom,Alan T. Hirsch,M. Dramaix,G DeBacker,J.C. Wautrecht,Marcel Kornitzer,A.B. Newman,Mary Cushman,Kim Sutton-Tyrrell,Amanda J Lee,Jackie F. Price,Ralph B. D'Agostino,Joanne M. Murabito,Paul Norman,K. Jamrozik,J D Curb,K. H. Masaki,B.L. Rodriquez,J.M. Dekker,Lex M. Bouter,R.J. Heine,Giel Nijpels,C.D.A. Stehouwer,Luigi Ferrucci,Henri E J H Stoffers,J. D. Hooi,J.A. Knottnerus,Mats Ögren,B. Hedblad,J. C. M. Witteman,Monique M.B. Breteler,M. G. Myriam Hunink,Albert Hofman,M H Criqui,Robert Langer,Arnost Fronek,William R. Hiatt,Richard F. Hamman,Helaine E. Resnick,J. M. Guralnik,Mary M. McDermott +46 more